ANSWER: B

Rationale:

The Rawlins and Thompson classification organizes adverse drug reactions (ADRs) into types based on their relationship to pharmacological mechanism and dose. Type A reactions (Augmented) are the most common category, accounting for approximately 80% of all ADRs. They are predictable extensions of the drug's known pharmacological effect, dose-dependent (more drug produces more adverse effect), and directly related to the drug's mechanism of action at its target receptor or enzyme. Because Type A reactions arise from known pharmacology, they can generally be anticipated, predicted, and managed by dose reduction or drug discontinuation. Examples include bradycardia from beta-blockers, hypoglycemia from insulin or sulfonylureas, bleeding from anticoagulants, and constipation from opioids. Option A describes Type B (Bizarre) reactions — unpredictable, dose-independent, immunologically mediated or idiosyncratic reactions unrelated to pharmacological mechanism, exemplified by anaphylaxis to penicillin, halothane hepatitis, and HIT. Option C describes Type C (Chronic/Continuing) or elements of Type B depending on the specific classification scheme used — idiosyncratic, genetically mediated reactions are Type B. Option D describes Type D (Delayed) reactions — carcinogenesis (e.g., alkylating agents), teratogenesis (e.g., thalidomide), and mutagenesis that manifest long after drug exposure. Option E does not correspond to any standard Rawlins and Thompson classification type.

ANSWER: D

Rationale:

The clinical presentation — urticaria, angioedema, and bronchospasm occurring within minutes of drug administration — is the hallmark of Type I immediate hypersensitivity (anaphylaxis or anaphylactoid reaction). The Gell and Coombs Type I mechanism requires two exposures: initial sensitization, during which the drug (or its haptenated metabolite conjugated to a carrier protein) stimulates B cells to produce antigen-specific IgE antibodies that bind to high-affinity FcRI receptors on mast cells and circulating basophils; and re-exposure, during which the drug antigen cross-links adjacent IgE molecules on these cells, triggering rapid degranulation and release of preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandin D2, leukotriene C4/D4/E4, platelet-activating factor). These mediators produce the clinical triad of urticaria/angioedema (histamine-mediated vasodilation and increased vascular permeability), bronchospasm (leukotriene-mediated), and potentially cardiovascular collapse. Option A describes Type II cytotoxic hypersensitivity — exemplified by drug-induced hemolytic anemia (methyldopa, penicillin), thrombocytopenia, and neutropenia, where the drug coats cell surfaces and IgG/IgM antibodies target these drug-coated cells. Option B describes Type III immune complex hypersensitivity — exemplified by serum sickness (urticaria, fever, arthralgias, lymphadenopathy occurring 1–3 weeks after drug exposure), where circulating drug-antibody immune complexes deposit in tissues and activate complement. Option C describes Type IV delayed-type hypersensitivity — exemplified by allergic contact dermatitis, Stevens-Johnson syndrome/TEN (via CD8+ T cell-mediated keratinocyte apoptosis), and drug reaction with eosinophilia and systemic symptoms (DRESS), with onset 48 hours to weeks after exposure. Option E describes a pseudoallergic (anaphylactoid) reaction — clinically identical to Type I but without IgE and without prior sensitization (e.g., radiocontrast media, vancomycin "red man syndrome" from direct mast cell activation by rapid infusion).

ANSWER: B

Rationale:

HIT is a prothrombotic immune-mediated adverse drug reaction — one of the most clinically dangerous and pharmacologically counterintuitive drug reactions encountered in clinical practice. The pathophysiology begins with heparin binding to platelet factor 4 (PF4), a chemokine constitutively released from platelet alpha-granules. The heparin-PF4 complex is immunogenic — in susceptible patients (approximately 1–5% of those receiving unfractionated heparin), IgG antibodies (HIT antibodies) are generated against this complex. These IgG antibodies simultaneously bind PF4-heparin complexes on the platelet surface and engage the platelet FcRIIA (Fc gamma receptor IIA) receptor. FcRIIA engagement activates the platelet, triggering degranulation, thromboxane A2 generation, and platelet aggregation. Activated platelets are consumed by thrombosis and cleared by the reticuloendothelial system — producing thrombocytopenia. Simultaneously, tissue factor expression on endothelial cells and monocytes is upregulated, and thrombin generation is massively amplified — creating a profoundly prothrombotic milieu. The clinical consequence is HIT syndrome: thrombocytopenia (platelet count typically falling by >50% from baseline) with paradoxical venous or arterial thrombosis (HITT), most commonly deep vein thrombosis, pulmonary embolism, limb ischemia, and stroke. Management requires immediate heparin cessation and substitution with a non-heparin anticoagulant (argatroban, fondaparinux, bivalirudin) — platelet transfusion is contraindicated as it "fuels the fire." Option A describes immune thrombocytopenic purpura or bone marrow suppression mechanisms, not HIT. Option C is incorrect — HIT is antibody-mediated (Type II Gell-Coombs) but the mechanism is FcR-mediated platelet activation, not complement-mediated lysis. Option D describes the mechanism of GPIIb/IIIa inhibitors (abciximab, tirofiban), not heparin. Option E is pharmacologically incorrect — heparin does not chelate calcium ions; it potentiates antithrombin III activity on serine protease coagulation factors.

ANSWER: B

Rationale:

hERG (human Ether-à-go-go Related Gene, KCNH2) encodes the alpha subunit of the rapid component of the delayed rectifier potassium current (IKr) in ventricular cardiomyocytes. IKr is a major repolarizing current in phase 3 of the ventricular action potential — it allows potassium efflux that restores the membrane potential toward the resting state after depolarization. The hERG channel has a uniquely large inner vestibule and a hydrophobic binding site that makes it susceptible to block by a remarkably diverse range of structurally unrelated drugs. When IKr is blocked, repolarization is delayed, prolonging the action potential duration (APD) and the corresponding QT interval on the surface ECG. In vulnerable individuals (those with underlying long QT risk factors: female sex, hypokalemia, hypomagnesemia, bradycardia, congenital long QT syndrome, structural heart disease, or polypharmacy with multiple QT-prolonging agents), the prolonged APD creates the electrophysiological substrate for early afterdepolarizations (EADs) — spontaneous depolarizations arising from incompletely repolarized myocytes during phase 2 or 3 of the action potential. EADs can trigger triggered activity that initiates TdP — a polymorphic ventricular tachycardia with characteristic twisting of the QRS axis around the isoelectric baseline. TdP may self-terminate or degenerate into ventricular fibrillation and sudden cardiac death. Option A is incorrect — hERG channels are expressed in ventricular myocytes, not sinoatrial node pacemaker cells; QT prolongation reflects ventricular repolarization delay, not RR interval changes. Option C is incorrect — the bundle of His is not the site of hERG-mediated QT effects; AV nodal conduction delay produces PR prolongation, not QT prolongation. Option D is incorrect — hERG channel blockade (not activation) prolongs QT; hERG activation would shorten APD. Option E is incorrect — hERG channels are potassium channels regulating membrane repolarization, not calcium handling; DADs (caused by calcium overload from digitalis toxicity or catecholamine excess) are a separate arrhythmia mechanism.

ANSWER: B

Rationale:

This is a pharmacokinetic drug interaction at the level of hepatic metabolism. Warfarin is administered as a racemic mixture; the S-enantiomer is approximately 3–5 times more potent as an anticoagulant and is metabolized almost exclusively by CYP2C9. Fluconazole is a potent, mechanism-based CYP2C9 inhibitor (as well as a CYP3A4 inhibitor). Inhibition of CYP2C9 reduces the hepatic clearance of S-warfarin, causing its plasma concentration to rise substantially. The increased S-warfarin plasma concentration produces greater inhibition of vitamin K epoxide reductase complex 1 (VKORC1) — warfarin's pharmacological target — reducing the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and elevating the INR. This interaction is clinically well-documented and dangerous: INR values can double or triple within days of fluconazole initiation in warfarin-maintained patients, creating serious bleeding risk. The interaction is pharmacokinetic (altered metabolism) rather than pharmacodynamic (interaction at the level of drug targets). Option A is incorrect — this is a pharmacokinetic interaction; fluconazole does not inhibit VKORC1. Option C is incorrect — fluconazole does not primarily alter warfarin absorption; it is a metabolic inhibitor. Option D is incorrect — fluconazole does not compete with warfarin for binding to clotting factors; such pharmacodynamic antagonism is not the mechanism. Option E is incorrect — warfarin is primarily eliminated by hepatic CYP2C9 metabolism, not renal tubular secretion; this is a hepatic metabolic, not a renal, interaction.

ANSWER: C

Rationale:

Aminoglycosides (gentamicin, tobramycin, amikacin) and loop diuretics (furosemide, ethacrynic acid) are both nephrotoxic and ototoxic agents that, when used concurrently, produce additive and potentially synergistic toxicity at both organ targets. Aminoglycoside nephrotoxicity results from uptake of cationic aminoglycoside molecules into proximal tubular epithelial cells via megalin-mediated endocytosis, leading to lysosomal accumulation, lipid peroxidation, mitochondrial dysfunction, and cell death — producing non-oliguric acute kidney injury typically appearing after 5–7 days of therapy. Furosemide reduces renal medullary blood flow by blocking the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, impairing countercurrent multiplication and reducing renal medullary perfusion — this hemodynamic impairment exacerbates aminoglycoside-induced proximal tubular ischemia. Additionally, furosemide-induced volume contraction reduces renal blood flow, increasing aminoglycoside residence time in the kidney. For ototoxicity, both aminoglycosides (cochlear hair cell destruction via reactive oxygen species) and ethacrynic acid in particular (endolymph electrolyte disruption) target the inner ear through distinct but additive mechanisms. Option A is incorrect — metformin-fluoroquinolone interaction involves hypoglycemia risk (fluoroquinolones affect insulin secretion) rather than nephrotoxicity through the mechanism described. Option B describes intended therapeutic synergy, not an adverse pharmacodynamic interaction. Option D correctly identifies a pharmacodynamic drug interaction (increased bleeding risk) but the mechanism is not nephrotoxicity. Option E describes a pharmacodynamic interaction causing excessive bradycardia, not nephrotoxicity — though non-dihydropyridine CCBs (verapamil, diltiazem) combined with beta-blockers carry this risk more than dihydropyridines.

ANSWER: B

Rationale:

The lithium-NSAID interaction is a pharmacokinetic drug interaction at the level of renal excretion — specifically through NSAID-mediated impairment of renal prostaglandin synthesis and its downstream effect on GFR and lithium clearance. Lithium is a monovalent cation that is almost entirely renally eliminated — it undergoes glomerular filtration and approximately 80% proximal tubular reabsorption (sharing sodium reabsorption mechanisms), with no meaningful hepatic metabolism and no plasma protein binding. Renal prostaglandins (particularly PGE2 and PGI2), synthesized by COX-1 and COX-2 in the kidney, are vasodilatory and serve a critical homeostatic role in maintaining renal blood flow and GFR when renal perfusion is threatened. Ibuprofen inhibits both COX-1 and COX-2, reducing intrarenal prostaglandin synthesis. In the presence of reduced prostaglandin-mediated vasodilation, afferent arteriolar tone increases (vasoconstriction is unopposed), GFR falls, and the filtered load of lithium decreases. Simultaneously, reduced GFR activates compensatory sodium (and lithium) reabsorption in the proximal tubule. The combined effect of reduced filtration and increased proximal reabsorption markedly reduces lithium clearance — plasma concentrations rise within days to toxic levels (>1.5 mEq/L), producing the neurological toxicity of tremor, ataxia, confusion, and in severe cases seizures and irreversible cerebellar damage. This interaction is not limited to ibuprofen but applies to all NSAIDs including indomethacin (most severe) and celecoxib (less severe). Acetaminophen (paracetamol) does not carry this risk and is the preferred analgesic in lithium-treated patients. Option A is incorrect — lithium is not metabolized by CYP enzymes; it is eliminated unchanged by the kidney. Option C is incorrect — lithium has no significant plasma protein binding; displacement is not a relevant mechanism. Option D is incorrect — lithium reabsorption is predominantly passive (following sodium), not actively secreted via P-glycoprotein. Option E is incorrect — lithium does not form chelate complexes with NSAIDs in the GI tract; this is not a recognized mechanism.

ANSWER: C

Rationale:

Female sex is the strongest and most consistently identified independent clinical risk factor for drug-induced QT prolongation and TdP. Women have a physiologically longer baseline QT interval than men (approximately 20 ms longer after correction for heart rate) — a sex difference that becomes apparent after puberty and is modulated by sex hormones throughout life. The mechanistic basis is hormonal: estrogen downregulates hERG channel expression and reduces IKr current density, while testosterone upregulates hERG and increases IKr. The net effect is that women have less repolarization reserve — a smaller safety margin between their baseline QT interval and the threshold for EAD formation. When a QT-prolonging drug (which reduces IKr by blocking hERG) is added to this reduced reserve, women reach the arrhythmogenic threshold at lower drug doses and lower plasma concentrations than men. Epidemiological data consistently demonstrate that women account for approximately 70% of drug-induced TdP cases across all drug classes studied, including antiarrhythmics, antihistamines, antipsychotics, and antibiotics. This sex difference has important regulatory and prescribing implications — female sex is listed as a risk factor for TdP in the prescribing information for all drugs with significant QT prolongation potential. Option A is incorrect — testosterone promotes hERG expression and increases IKr, which is cardioprotective against QT prolongation; male sex is associated with lower TdP risk, not higher. Option B is incorrect — younger patients generally have better repolarization reserve; age over 60–65 years is a risk factor (reduced repolarization reserve, comorbidities, polypharmacy), not age under 40. Option D is incorrect — while specific KCNH2 loss-of-function variants occur in various populations, African American ethnicity is not a universally established independent TdP risk factor in the same manner as female sex, hypokalemia, or bradycardia. Option E is incorrect — adipose tissue sequestration of lipophilic drugs reduces, not increases, their effective plasma concentration and cardiac exposure; obesity is not an established independent TdP risk factor through this mechanism.